Federated Hermes
INZY

Federated Hermes’s Inozyme Pharma INZY Stock Holding History

Federated Hermes’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,191
Closed -$17.5K – 2120
2025
Q1 		$17.5K Buy
19,191
+14,095
+277% +$19.5K ﹤0.01% 1745
2024
Q4 		$14.1K Buy
+5,096
New +$19.4K ﹤0.01% 1805
2023
Q1 		– Sell
-1,381
Closed -$1.45K – 2186
2022
Q4 		$1.45K Sell
1,381
-152
-10% -$266 ﹤0.01% 2031
2022
Q3 		$4K Buy
+1,533
New +$5.55K ﹤0.01% 1911
2022
Q2 		– Sell
-451
Closed -$2K – 2221
2022
Q1 		$2K Buy
451
+330
+273% +$1.94K ﹤0.01% 2027
2021
Q4 		$1K Buy
+121
New +$1.04K ﹤0.01% 2122

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Federated Hermes's INZY Position: Q2 2025 in Review

Federated Hermes sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 19,191 shares — an estimated $17.5K sold.

Federated Hermes first reported a position in INZY in Q4 2021 and held it in 6 quarters. The position peaked at $17.5K in Q1 2025. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Federated Hermes reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Federated Hermes sold 19,191 Inozyme Pharma shares in Q2 2025, an estimated $17.5K.
  • Federated Hermes first reported a position in Inozyme Pharma in Q4 2021 and held it in 6 quarters.
  • Federated Hermes's Inozyme Pharma position peaked at $17.5K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.